Kratom: From Traditional Medicine to Clinical Research

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen. Dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

By WorldCannabisCongress.com Editorial Team | Last verified: July 2026

Overview: Kratom in Traditional and Contemporary Context

Mitragyna speciosa, commonly known as kratom, is an evergreen tree native to the rainforests of Southeast Asia. The WorldCannabisCongress.com Editorial Team recognizes kratom as a distinctive ethnobotanical with a centuries-long history of use in the region and a growing body of pharmacological research that distinguishes it from both cannabis-family plants and typical dietary supplements. Kratom leaves contain a diverse alkaloid profile that produces dose-dependent effects ranging from stimulation at lower doses to sedation and analgesia at higher doses—a pharmacological duality that has attracted both traditional practitioners and modern researchers.

Unlike cannabis, kratom does not interact with endocannabinoid receptors; rather, its primary mechanisms involve opioid receptor agonism (particularly 7-hydroxymitragynine) and monoamine neurotransmitter modulation. This distinction is clinically important. The plant’s legal status remains contested globally: it is banned in several countries including Thailand (historically, though traditional use persists), while remaining legal and largely unregulated in North America and Europe. Understanding kratom requires bridging ethnobotanical knowledge with emerging pharmacological evidence while acknowledging significant gaps in long-term safety and efficacy data.

Ethnobotanical History and Traditional Applications

Kratom has been integrated into Southeast Asian daily life for at least 150 years, and anthropological evidence suggests use may extend further back. In Indonesia—particularly on the island of Sumatra—kratom leaves were traditionally chewed fresh or brewed as a tea by agricultural laborers, small-scale miners, and manual workers seeking sustained energy and pain relief during long working hours. The practice was not confined to occupational use; kratom also held social significance in communal gatherings and informal ceremonies.

In Malaysia and Thailand, traditional medicine practitioners recognized kratom’s capacity to modulate pain and mood, incorporating it into remedies for musculoskeletal discomfort and emotional distress. Older texts from the region reference kratom’s “warming” properties in traditional frameworks. Unlike the regulatory suppression that cannabis experienced in many Western countries, kratom remained relatively obscure in Western herbalism until the late 20th century, when Internet commerce and ethnobotanical communities brought it to global attention. This relatively recent Western adoption means traditional knowledge documentation is still developing, with much oral history remaining uncollected in academic literature.

Phytochemistry: Active Alkaloids and Their Proposed Mechanisms

Kratom’s pharmacological profile is dominated by alkaloids—nitrogenous organic compounds that interact with human neurotransmitter systems. Research identifies over 40 alkaloids in kratom leaf material, though the two most studied are mitragynine and 7-hydroxymitragynine.

Mitragynine: The Primary Alkaloid

Mitragynine comprises 0.5–1.5% of dried kratom leaf by weight and serves as the primary marker compound for quality control. In vitro and animal studies indicate that mitragynine acts as a partial agonist at mu (μ) and delta (δ) opioid receptors, as well as an agonist at alpha-2 adrenergic receptors. This multi-receptor activity may explain kratom’s dose-dependent effects: lower doses (1–2 g) tend to produce stimulation via alpha-2 adrenergic activation and monoamine enhancement, while higher doses (3–5 g) appear to shift toward opioid-mediated analgesia and sedation. Mitragynine also shows activity at serotonin 5-HT7 receptors in preliminary models, potentially contributing to mood and sleep effects.

7-Hydroxymitragynine: The Secondary Alkaloid with Potent Effects

Present in much lower concentration (0.004–0.3% of leaf material), 7-hydroxymitragynine displays approximately 46 times greater affinity for mu opioid receptors than mitragynine in laboratory assays. This compound may account for kratom’s analgesic potency at higher doses, though its contribution to the overall pharmacological profile remains incompletely characterized. The ratio of mitragynine to 7-hydroxymitragynine varies by kratom vein color and geographic origin, which may partially explain user-reported differences in effect between “red vein,” “green vein,” and “white vein” strains.

Secondary Alkaloids and Polyphenols

Speciogynine, paynantheine, and speciociliatine are abundant secondary alkaloids whose individual contributions to kratom’s effects remain largely unexplored in human models. The leaf also contains flavonoids, catechins, and polyphenolic antioxidants that may have anti-inflammatory and cytoprotective roles, though human evidence for these components is minimal. The whole-plant profile suggests kratom operates as a complex phytochemical system rather than a single-compound medicine—a property consistent with traditional use and relevant to standardization discussions.

Scientific Evidence: Current State of Research

Modern kratom research is nascent compared to established botanicals. Most published studies are observational, in vitro, or conducted in animal models. Human clinical trials remain limited, creating a gap between traditional use claims and rigorous evidence. The WorldCannabisCongress.com Editorial Team emphasizes this limitation while reviewing available findings.

Pain Management and Analgesia

The most consistent evidence base surrounds kratom’s analgesic properties. Multiple observational and survey-based studies report that kratom users self-administer the herb for chronic pain conditions including back pain, arthritis, and fibromyalgia. A 2019 retrospective online survey of over 8,000 kratom users found that pain relief was the most commonly cited reason for use (91% of respondents), with users reporting significant subjective improvements. However, this evidence derives from self-report and lacks placebo controls. A 2020 study published in the Journal of the American Medical Association found survey data consistent with analgesia, but acknowledged the lack of randomized controlled trials. Animal models using mitragynine have demonstrated dose-dependent analgesic effects in thermal and mechanical pain assays, supporting the plausibility of human analgesia, but do not constitute proof of clinical efficacy.

Opioid Use Disorder and Withdrawal Management

Emerging evidence suggests kratom may support individuals managing opioid dependence, though this application carries significant caution and regulatory scrutiny. A 2019 ethnographic study documented kratom use among individuals self-managing opioid withdrawal symptoms, with reported reductions in craving and withdrawal discomfort. A 2020 online survey of 2,798 kratom users found 37% reported using kratom to manage opioid withdrawal or reduce opioid intake. However, no randomized, placebo-controlled trials have tested kratom’s efficacy in opioid use disorder, and concerns exist regarding kratom’s own dependence potential with chronic use. The U.S. FDA has issued warnings about kratom’s promotion as an opioid alternative, citing insufficient evidence and safety concerns. Healthcare providers remain divided on whether kratom represents a harm-reduction tool or a gateway substance, underscoring the need for rigorous clinical investigation before clinical recommendation.

Mood, Energy, and Cognitive Function

Survey data indicate kratom users report improved mood, reduced anxiety, and enhanced focus, particularly at lower doses. A 2017 qualitative analysis of online kratom forums identified energy and mood uplift as secondary motivations for use. However, objective measures of mood or cognitive performance via randomized, blinded designs are absent from the published literature. Animal studies suggest mitragynine may influence dopamine and serotonin pathways in ways consistent with mood and motivation enhancement, but translating these findings to human clinical contexts remains speculative. No standardized psychometric assessments have been conducted in human kratom users.

Inflammation and Immune Function

In vitro studies have demonstrated that kratom alkaloid extracts suppress pro-inflammatory cytokine production in macrophage and lymphocyte cultures. A 2021 review noted that kratom’s polyphenolic content may contribute antioxidant effects, potentially supporting immune homeostasis. However, clinical trials evaluating inflammatory markers, immune cell counts, or infection rates in kratom users are entirely absent. These findings remain preliminary and cannot be translated to human health claims without human evidence.

Dosing, Standardization, and Quality Considerations

Kratom dosing varies considerably based on vein color, individual alkaloid profile, desired effect, and user tolerance. Traditional and contemporary use suggest the following framework:

Dose Ranges

Low dose (stimulant effect): 1–2 g of dried leaf powder; typically produces energy, focus, and mild euphoria

Moderate dose (balanced effect): 2–4 g; intermediate between stimulation and sedation

High dose (analgesic/sedative effect): 4–6 g; associated with pain relief, relaxation, and sleep promotion

Doses exceeding 8–10 g are reported by some users but carry elevated risk of adverse effects including nausea and dependence potential.

Standardization Challenges

Unlike pharmaceuticals or rigorously standardized herbal medicines, kratom products vary dramatically in alkaloid content. Whole-leaf powder is typically unstandardized; mitragynine content ranges from 0.5–1.5% depending on harvest conditions, processing methods, and leaf maturity. Extracts are often standardized to mitragynine (25–50%), but the concentration of 7-hydroxymitragynine is rarely disclosed, and many products lack third-party testing for alkaloid content or contaminants. The American Kratom Association (AKA) has proposed a “Kratom Consumer Protection Act” establishing quality standards, but these remain voluntary and non-binding at the federal level. Consumers seeking consistent effects should prioritize suppliers offering:

• Third-party laboratory testing for alkaloid content (mitragynine and ideally 7-hydroxymitragynine quantification)
• Heavy metal and microbial contamination testing
• Chain of custody documentation from harvest to consumer
• Batch-to-batch consistency data

Forms, Preparations, and Bioavailability

Kratom is available in multiple forms, each with distinct bioavailability and user convenience profiles.

Whole Leaf Powder

Related Articles

• CBD Joint Pain Topicals 2026: Third-Party Lab Results and Co…
• CBD: From Traditional Medicine to Clinical Research
• Cannabis Social Equity Programs 2026: State-by-State Licensi…
• Cannabis Testing Laboratory Rankings 2026: ISO Certification…